Overview

Price chart · mood · technical indicators

MRK

Merck & Company Incstock Healthcare

Drug Manufacturers - General

$113.1343.13%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$73.31$125.14

Current: $113.13

Idea: EMA

1Y Return

+39.0%

Sharpe 3Y

0.68

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

MRK

+43.13%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio31.51Forward 21.93

EPS (TTM)$3.56-19.3% YoY

Profit margin13.6%HEALTHCARE

Market cap$277.02BMega cap

Wall Street coverage

$129.74median target· current $127.57 (+1.7%)29 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 21.93
PEG ratio: 3.43
P/B: 5.27
P/S (TTM): 4.21
EV/EBITDA: 23.97

Profitability & growth

ROE (TTM): 36.9%
Operating margin: 38.1%
Revenue growth YoY: 4.9%
Dividend yield: 3.0%
Beta: 0.28

Last earnings

Apr 30, 2026 · Estimate $-1.50 · Reported $-1.28

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Merck & Company Inc

Company profile

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NYSE
Country: USA
Currency: USD

Company profile

HQ: 126 EAST LINCOLN AVENUE, RAHWAY, NJ
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$277.02B

Shares outstanding$2.47B

52W high$124.22

52W low$70.74

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

MRK

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Aptar Injectable Sales Soar Amid Pharmaceutical Production Boom

Jim Cramer on Merck & Co.: “The Stock’s Starting to Come Back”

What Makes Merck & Co. (MRK) an Investment Bet?

Truist Financial Corp Boosts Stock Holdings in Merck & Co., Inc. $MRK

Merck & Co., Inc. $MRK Shares Sold by Intact Investment Management Inc.

Flu Vaccine Market is expected to Hit US$ 10.74 billion by 2033 |

Merck & Co., Inc. $MRK Shares Sold by M&T Bank Corp

FSA Advisors Inc. Makes New Investment in Merck & Co., Inc. $MRK

The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals

Jefferies initiates Compass Pathways stock with buy on depression drug By Investing.com

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

Moderna’s strong vaccine sales outside US far surpass estimates

Pfizer Scores an FDA Approval and a Patent Win in One Week. Here’s What the Stock Could Return by 2028

Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx

Wilkins Investment Counsel Inc. Reduces Holdings in Merck & Co., Inc. $MRK

PKO Investment Management Joint Stock Co Sells 38,875 Shares of Merck & Co., Inc. $MRK

Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

Mitsubishi UFJ Trust & Banking Corp Sells 202,370 Shares of Organon & Co. $OGN

CX Institutional Buys 9,768 Shares of Merck & Co., Inc. $MRK

Benjamin Edwards Inc. Trims Position in Merck & Co., Inc. $MRK

About Merck & Company Inc

Classification

Company profile

MRK

Market Comparison

MRK Market Analysis

Overview

MRK

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Aptar Injectable Sales Soar Amid Pharmaceutical Production Boom

Jim Cramer on Merck & Co.: “The Stock’s Starting to Come Back”

What Makes Merck & Co. (MRK) an Investment Bet?

Truist Financial Corp Boosts Stock Holdings in Merck & Co., Inc. $MRK

Merck & Co., Inc. $MRK Shares Sold by Intact Investment Management Inc.

Flu Vaccine Market is expected to Hit US$ 10.74 billion by 2033 |

Merck & Co., Inc. $MRK Shares Sold by M&T Bank Corp

FSA Advisors Inc. Makes New Investment in Merck & Co., Inc. $MRK

The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals

Jefferies initiates Compass Pathways stock with buy on depression drug By Investing.com

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

Moderna’s strong vaccine sales outside US far surpass estimates

Pfizer Scores an FDA Approval and a Patent Win in One Week. Here’s What the Stock Could Return by 2028

Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx

Wilkins Investment Counsel Inc. Reduces Holdings in Merck & Co., Inc. $MRK

PKO Investment Management Joint Stock Co Sells 38,875 Shares of Merck & Co., Inc. $MRK

Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

Mitsubishi UFJ Trust & Banking Corp Sells 202,370 Shares of Organon & Co. $OGN

CX Institutional Buys 9,768 Shares of Merck & Co., Inc. $MRK

Benjamin Edwards Inc. Trims Position in Merck & Co., Inc. $MRK

About Merck & Company Inc

Classification

Company profile

MRK

Market Comparison